Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients

Bibliography

• Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol 2002;118(4):1071-7
   PubMed Web of Science ®Google Scholar
• Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 2006;47(8):1477-80
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94(2):448-54
   PubMed Web of Science ®Google Scholar
• Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991;78:1545-51
   PubMed Web of Science ®Google Scholar
• Dhodapkar M, Tefferi A, Su J, Phyliky RL. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukaemia (B-CLL): a single institution study. Leukemia 1993;7(8):1232-5
   PubMed Web of Science ®Google Scholar
• Molica S, Brugiatelli M, Callea V, et al. Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 1994;52(4):216-21
   PubMed Web of Science ®Google Scholar
• Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004;104(6):1850-4
   PubMed Web of Science ®Google Scholar
• Sellick GS, Catovsky D, Houlston RS. Familial chronic lymphocytic leukemia. Semin Oncol 2006;33(2):195-201
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338(21):1506-14
   PubMed Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100(4):1410-16
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986;62:567-75
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern – the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984;64:642-8
   PubMed Web of Science ®Google Scholar
• Gray JL, Jacobs A, Block M. Bone marrow and peripheral blood lymphocytosis in the prognosis of chronic lymphocytic leukemia. Cancer 1974;33(4):1169-78
   PubMed Web of Science ®Google Scholar
• Alt FW, Yancopoulos GD, Blackwell TK, et al. Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J 1984;3(6):1209-19
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simonsson B, Gronowitz JS, Nilsson K. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur J Haematol 1987;38(4):331-7
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 1984;54(11):2450-5
   PubMed Web of Science ®Google Scholar
• Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93(5):1732-7
   PubMed Web of Science ®Google Scholar
• Knauf WU, Ehlers B, Mohr B, et al. Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Blood 1997;89(11):4241-2
   PubMed Web of Science ®Google Scholar
• Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1997;27(5-6):523-32
   PubMed Web of Science ®Google Scholar
• Di Giovanni S, Valentini G, Carducci P, Giallonardo P. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 1989;81(4):181-5
   PubMed Web of Science ®Google Scholar
• Keating MJ. Chronic lymphocytic leukemia in the next decade: where do we go from here? Semin Hematol 1998;35(3 Suppl 3):27-33
   PubMedGoogle Scholar
• Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4070-8
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15(6):288-94
   PubMedGoogle Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840-7
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102(5):553-63
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Sahota SS, Ottensmeier CH, et al. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 2001;83:81-116
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194(11):1625-38
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194(11):1639-47
   PubMed Web of Science ®Google Scholar
• Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100(4):1404-9
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100(4):1177-84
   PubMed Web of Science ®Google Scholar
• Lanham S, Hamblin T, Oscier D, et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101(3):1087-93
   PubMed Web of Science ®Google Scholar
• Nedellec S, Renaudineau Y, Bordron A, et al. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J Immunol 2005;174(6):3749-56
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102(8):1515-25
   PubMed Web of Science ®Google Scholar
• Mauerer K, Zahrieh D, Gorgun G, et al. Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br J Haematol 2005;129(4):499-510
   PubMed Web of Science ®Google Scholar
• Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMVspecific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood 2003;102(3):1057-63
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3 – 21 gene display highly restricted Vlambda2 – 14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101(12):4952-7
   Google Scholar
• Tobin G, Soderberg O, Thunberg U, Rosenquist R. V(H)3 – 21 gene usage in chronic lymphocytic leukaemia – characterization of a new subgroup with distinct molecular features and poor survival. Leuk Lymphoma 2004;45(2):221-8
   PubMed Web of Science ®Google Scholar
• Tobin G, Rosenquist R. Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol 2005;22(3):217-28
   PubMed Web of Science ®Google Scholar
• Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990;76(3):562-9
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989;169(1):255-68
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103(12):4389-95
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99(3):1023-9
   PubMed Web of Science ®Google Scholar
• Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005;90(3):391-9
   PubMed Web of Science ®Google Scholar
• Seiler T, Dohner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006;33(2):186-94
   Google Scholar
• Boonstra JG, Van Lom K, Langerak AW, et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of threeapproaches to analyze its expression. Cytometry B Clin Cytom 2006;70(3):136-41
   PubMedGoogle Scholar
• Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101(12):4944-51
   PubMed Web of Science ®Google Scholar
• Catherwood MA, Matthews C, Niblock R, et al. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Haematol 2006;76(4):294-8
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348(18):1764-75
   PubMed Web of Science ®Google Scholar
• Carreras J, Villamor N, Colomo L, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005;205(4):507-13
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363(9403):105-11
   PubMed Web of Science ®Google Scholar
• Bosch F, Villamor N. ZAP-70 expression in CLL: a new parameter for an old disease. Haematologica 2003;88(7):724-6
   PubMed Web of Science ®Google Scholar
• Bosch F, Muntanola A, Gine E, et al. Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006;70(4):214-17
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351(9):893-901
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24(6):969-75
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108(3):853-61
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Morilla A, Osuji N, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005;104(10):2124-32
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trumper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19(5):750-8
   PubMed Web of Science ®Google Scholar
• Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006;17(4):683-90
   PubMed Web of Science ®Google Scholar
• Heintel D, Kroemer E, Kienle D, et al. High expression of activationinduced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 2004;18(4):756-62
   PubMed Web of Science ®Google Scholar
• Nuckel H, Huttmann A, Klein-Hitpass L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47(6):1053-61
   PubMed Web of Science ®Google Scholar
• Van't Veer MB, Brooijmans AM, Langerak AW, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006;91(1):56-63
   PubMed Web of Science ®Google Scholar
• Van Bockstaele F, Pede V, Janssens A, et al. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem 2007;53(2):204-12
   PubMed Web of Science ®Google Scholar
• Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106(2):650-7
   PubMed Web of Science ®Google Scholar
• Koller C, Bekele BN, Zhou X, et al. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 2006;108(3):1001-6
   PubMed Web of Science ®Google Scholar
• Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101(32):11755-60
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007;109(11):4944-51
   PubMed Web of Science ®Google Scholar
• Wahlfors J, Hiltunen H, Heinonen K, et al. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992;80(8):2074-80
   PubMed Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82(6):1820-8
   PubMed Web of Science ®Google Scholar
• Raval A, Lucas DM, Matkovic JJ, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005;23(17):3877-85
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006;33(2):174-85
   PubMed Web of Science ®Google Scholar
• Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000;14(8):1414-18
   PubMed Web of Science ®Google Scholar
• Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002;100(9):3344-51
   PubMed Web of Science ®Google Scholar
• Kara IO, Sahin B, Gunesacar R. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther 2007;24(1):29-40
   PubMed Web of Science ®Google Scholar
• Lai R, O'Brien S, Maushouri T, et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 2002;95(5):1071-5
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100(4):1215-19
   PubMed Web of Science ®Google Scholar
• Molica S, Vitelli G, Levato D, Giannarelli D, Gandolfo GM. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 2001;92(4):713-19
   PubMed Web of Science ®Google Scholar
• Molica S, Vitelli G, Mirabelli R, et al. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Eur J Haematol 2006;76(1):51-7
   PubMed Web of Science ®Google Scholar
• Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005;105(4):1694-8
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E, Juszczynski P, Szmigielska-Kaplon A, et al. Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia? Haematologica 2007;92(5):710-11
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc 2007;82(4):449-53
   PubMed Web of Science ®Google Scholar
• Manocha S, Matrai Z, Osthoff M, Carter A, Pettitt AR. Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44(5):797-800
   PubMed Web of Science ®Google Scholar
• Efstathiou S, Tsioulos D, Zacharos I, et al. The prognostic role of CD5 negativity in B-cell chronic lymphocytic leukaemia: a case-control study. Haematologia (Budap) 2002;32(3):209-18
   PubMedGoogle Scholar
• Varga L, Czink E, Miszlai Z, et al. Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1995;99(1):112-16
   PubMed Web of Science ®Google Scholar
• Ocana E, Delgado-Perez L, Campos-Caro A, et al. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 2007;92(3):349-56
   PubMed Web of Science ®Google Scholar
• Josefsson P, Geisler CH, Leffers H, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007;109(11):4973-9
   PubMed Web of Science ®Google Scholar
• Buhl AM, Jurlander J, Geisler CH, et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol 2006;76(6):455-64
   PubMed Web of Science ®Google Scholar
• Scielzo C, Ghia P, Conti A, et al. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest 2005;115(6):1644-50
   PubMed Web of Science ®Google Scholar
• Matthews C, Catherwood MA, Larkin AM, et al. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47(11):2308-13
   PubMed Web of Science ®Google Scholar
• Pemberton NC, Paneesha S, Hiller L, et al. The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47(7):1239-44
   PubMed Web of Science ®Google Scholar
• Au WY, Fung A, Wong KF, Chan CH, Liang R. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leuk Lymphoma 2006;47(10):2189-93
   PubMed Web of Science ®Google Scholar
• Frey UH, Nuckel H, Sellmann L, et al. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006;12(19):5686-92
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109(1):290-7
   PubMed Web of Science ®Google Scholar
• Tobin G, Skogsberg A, Thunberg U, et al. Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia. Leukemia 2005;19(5):871-3
   PubMed Web of Science ®Google Scholar
• Starczynski J, Pepper C, Pratt G, et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol 2005;23(7):1514-21
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Durig J, Duhrsen U, Siffert W. Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia 2004;18(11):1816-23
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Giles FJ, O'Brien S, et al. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res 2004;28(7):707-11
   PubMed Web of Science ®Google Scholar
• Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005;105(12):4807-12
   PubMed Web of Science ®Google Scholar
• Tchirkov A, Chaleteix C, Magnac C, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol 2004;15(10):1476-80
   PubMed Web of Science ®Google Scholar
• Bechter OE, Eisterer W, Pall G, et al. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res 1998;58(21):4918-22
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Bomben R, Dal Bo M, et al. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. J Cell Physiol 2006;207(2):354-63
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109(11):4679-85
   PubMed Web of Science ®Google Scholar
• Molica S, Mauro FR, Callea V, et al. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005;46(4):553-60
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988;29(3):152-63
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H, et al. Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996;347:1432-8
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98(8):2319-25
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343(24):1750-7
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien SM. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol 2006;33(2):202-9
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98(1):29-35
   PubMed Web of Science ®Google Scholar
• Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996;88(6):2228-35
   PubMed Web of Science ®Google Scholar
• Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol 2005;23(13):2884-5
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89(7):2516-22
   PubMed Web of Science ®Google Scholar
• El Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82(11):3452-9
   PubMed Web of Science ®Google Scholar
• Geisler CH, Philip P, Christensen BE, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997;21(11-12):1011-23
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347(6):452-3
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103(9):3278-81
   PubMed Web of Science ®Google Scholar
• Dreger P, Van Biezen A, Brand R. Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukaemia (CLL): the EBMT experience. Blood 2000;96(Suppl 1):A482
   Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7
   PubMed Web of Science ®Google Scholar